On the public citation graph

Immune tolerance induction: What have we learned over time?

0 signed · 114 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jama.1988.03720010043038openalex-snapshot
Induction of Immune Tolerance to Factor VIII in Hemophiliacs With Inhibitors
inferredcites →https://doi.org/10.1016/s0140-6736(77)90871-6openalex-snapshot
MASSIVE FACTOR-VIII INFUSION IN HÆMOPHILIAC WITH FACTOR-VIII INHIBITOR, HIGH RESPONDER
inferredcites →https://doi.org/10.1046/j.1365-2516.1999.00195.xopenalex-snapshot
Tolerance induction using the Malmö treatment model 1982–1995
inferredcites →https://doi.org/10.1046/j.1365-2516.1999.00311.xopenalex-snapshot
German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies
inferredcites →https://doi.org/10.1046/j.1365-2516.1999.00354.xopenalex-snapshot
Induction of immune tolerance with recombinant factor VIII in haemophilia A patients with inhibitors
inferredcites →https://doi.org/10.1046/j.1365-2516.2000.00379.xopenalex-snapshot
Immune tolerance induction in the treatment of paediatric haemophilia A patients with factor VIII inhibitors
inferredcites →https://doi.org/10.1046/j.1365-2516.2001.00469.xopenalex-snapshot
Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry
inferredcites →https://doi.org/10.1046/j.1365-2516.2001.00530.xopenalex-snapshot
von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients
inferredcites →https://doi.org/10.1046/j.1365-2516.2003.00802.xopenalex-snapshot
Impact of inhibitor epitope profile on the neutralizing effect against plasma‐derived and recombinant factor VIII concentrates in vitro
inferredcites →https://doi.org/10.1055/s-0037-1612943openalex-snapshot
The North American Immune Tolerance Registry: Practices, Outcomes, Outcome Predictors
inferredcites →https://doi.org/10.1055/s-0037-1617018openalex-snapshot
ITI with high-dose FIX and combined immunosuppressive therapy in a patient with severe haemophilia B and inhibitor
inferredcites →https://doi.org/10.1055/s-0038-1648828openalex-snapshot
Immune Tolerance in Hemophilia-Principal Results from the International Registry
inferredcites →https://doi.org/10.1055/s-0038-1650655openalex-snapshot
Factor VIII Inhibitor Antibodies with C2 Domain Specificity Are Less inhibitory to Factor VIII Complexed with von Willebrand Factor
inferredcites →https://doi.org/10.1056/nejm198804143181503openalex-snapshot
Induction of Immune Tolerance in Patients with Hemophilia and Antibodies to Factor VIII by Combined Treatment with Intravenous IgG, Cyclophosphamide, and Factor VIII
inferredcites →https://doi.org/10.1111/bjh.12091openalex-snapshot
Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition)
inferredcites →https://doi.org/10.1111/bjh.12942openalex-snapshot
Effect of von W illebrand factor on inhibitor eradication in patients with severe haemophilia A : a systematic review
inferredcites →https://doi.org/10.1111/hae.12263openalex-snapshot
Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF ‐containing plasma‐derived FVIII concentrate
inferredcites →https://doi.org/10.1111/hae.12521openalex-snapshot
Adult haemophilia A patients with inhibitors: successful immune tolerance induction with a single FVIII / VWF product
inferredcites →https://doi.org/10.1111/hae.12608openalex-snapshot
Prompt immune tolerance induction at inhibitor diagnosis regardless of titre may increase overall success in haemophilia A complicated by inhibitors: experience of two US centres
inferredcites →https://doi.org/10.1111/hae.12730openalex-snapshot
US Guidelines for immune tolerance induction in patients with haemophilia a and inhibitors
inferredcites →https://doi.org/10.1111/hae.12857openalex-snapshot
Clinical overview of Fanhdi/Alphanate (plasma‐derived, VWF ‐containing FVIII concentrate) in immune tolerance induction in haemophilia A patients with inhibitors
inferredcites →https://doi.org/10.1111/hae.12986openalex-snapshot
Long‐term outcome of haemophilia A patients after successful immune tolerance induction therapy using a single plasma‐derived FVIII/VWF product: the long‐term ITI study
inferredcites →https://doi.org/10.1111/hae.13264openalex-snapshot
First‐line immune tolerance induction for children with severe haemophilia A: A protocol from the UK Haemophilia Centre Doctors' Organisation Inhibitor and Paediatric Working Parties
inferredcites →https://doi.org/10.1111/j.1365-2141.1986.tb04122.xopenalex-snapshot
Disappearance of factor VIII:C antibodies in patients with haemophilia A upon frequent administration of factor VIII in intermediate or low dose
inferredcites →https://doi.org/10.1111/j.1365-2516.1996.tb00022.xopenalex-snapshot
Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations
inferredcites →https://doi.org/10.1111/j.1365-2516.2005.01167.xopenalex-snapshot
Canadian multi‐institutional survey of immune tolerance therapy (ITT) – experience with the use of recombinant factor VIII for ITT
inferredcites →https://doi.org/10.1111/j.1365-2516.2006.01182.xopenalex-snapshot
Higher recovery of factor VIII (FVIII) with intermediate FVIII/von Willebrand factor concentrate than with recombinant FVIII in a haemophilia A patient with an inhibitor
inferredcites →https://doi.org/10.1111/j.1365-2516.2007.01484.xopenalex-snapshot
Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response
inferredcites →https://doi.org/10.1111/j.1365-2516.2007.01497.xopenalex-snapshot
International workshop on immune tolerance induction: consensus recommendations1
inferredcites →https://doi.org/10.1111/j.1365-2516.2007.01560.xopenalex-snapshot
Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors
inferredcites →https://doi.org/10.1111/j.1365-2516.2007.01620.xopenalex-snapshot
The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high‐titre inhibitors: association of clinical outcome with inhibitor epitope profile
inferredcites →https://doi.org/10.1111/j.1365-2516.2011.02577.xopenalex-snapshot
Immune tolerance induction with a factor VIII concentrate containing von Willebrand factor (Haemoctin SDH®) in 14 patients with severe haemophilia A
inferredcites →https://doi.org/10.1111/j.1365-2516.2011.02679.xopenalex-snapshot
Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A
inferredcites →https://doi.org/10.1111/j.1423-0410.1999.tb00015.xopenalex-snapshot
Induction of Immune Tolerance in Haemophilia A Inhibitor Patients by the ‘Bonn Protocol‘: Predictive Parameter for Therapy Duration and Outcome
inferredcites →https://doi.org/10.1111/j.1423-0410.2006.00828.xopenalex-snapshot
Fc function of a new intravenous immunoglobulin product: IGIV 10% triple virally inactivated solution
inferredcites →https://doi.org/10.1111/j.1538-7836.2005.01375.xopenalex-snapshot
Cellular immune responses in hemophilia: why do inhibitors develop in some, but not all hemophiliacs?
inferredcites →https://doi.org/10.1111/j.1538-7836.2007.02736.xopenalex-snapshot
Factor VIII‐specific memory B cells in patients with hemophilia A
inferredcites →https://doi.org/10.1111/j.1538-7836.2011.04493.xopenalex-snapshot
The use of a single von Willebrand factor‐containing, plasma‐derived FVIII product in hemophilia A immune tolerance induction: the US experience
inferredcites →https://doi.org/10.1136/bmj.281.6252.1388openalex-snapshot
Plasma exchange and human factor VIII concentrate in managing haemophilia A with factor VIII inhibitors.
inferredcites →https://doi.org/10.1177/2040620717721458openalex-snapshot
Current and emerging factor VIII replacement products for hemophilia A
inferredcites →https://doi.org/10.1182/asheducation-2016.1.657openalex-snapshot
Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches
inferredcites →https://doi.org/10.1182/blood-2003-07-2207openalex-snapshot
In vivo neutralization of a C2 domain–specific human anti–Factor VIII inhibitor by an anti-idiotypic antibody
inferredcites →https://doi.org/10.1182/blood-2005-03-1182openalex-snapshot
High-dose factor VIII inhibits factor VIII–specific memory B cells in hemophilia A with factor VIII inhibitors
inferredcites →https://doi.org/10.1182/blood-2008-09-174649openalex-snapshot
Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice
inferredcites →https://doi.org/10.1182/blood-2011-08-369132openalex-snapshot
The principal results of the International Immune Tolerance Study: a randomized dose comparison
inferredcites →https://doi.org/10.1182/blood.v62.1.141.141openalex-snapshot
Treatment of a high titer anti-factor-VIII antibody by continuous factor VIII administration: report of a case.
inferredcites →https://doi.org/10.1182/blood.v86.3.983.983openalex-snapshot
Low-dose immune tolerance induction in hemophilia A patients with inhibitors

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4789895openalex-extracted
Maternal Microchimerism Promotes Tolerance Induction Toward Factor VIII in Severe Haemophilia a Children with Inhibitors
inferred← citeshttps://doi.org/10.1002/rth2.12248openalex-snapshot
Low‐dose immune tolerance induction for children with hemophilia A with poor‐risk high‐titer inhibitors: A pilot study in China
inferred← citeshttps://doi.org/10.1007/978-3-030-93990-8_4openalex-snapshot
Immune Tolerance Induction in Patients with Hemophilia A
inferred← citeshttps://doi.org/10.1007/978-3-031-36739-7_18openalex-snapshot
Inga Marie Nilsson—“The Queen of Coagulation”
inferred← citeshttps://doi.org/10.1007/s12185-022-03359-zopenalex-snapshot
Longitudinal profiling of anti-factor VIII antibodies in Japanese patients with congenital hemophilia A during factor VIII replacement and immune-tolerance induction therapy
inferred← citeshttps://doi.org/10.1007/s12288-019-01218-2openalex-snapshot
Experience of Immune Tolerance Induction Therapy for Hemophilia A Patients with Inhibitors from a Single Center in India
inferred← citeshttps://doi.org/10.1016/j.htct.2021.02.010openalex-snapshot
Twelve months of emicizumab prophylaxis in a severe hemophilia A man with inhibitor who failed immune tolerance induction: effectiveness, economic, and safety outcomes
inferred← citeshttps://doi.org/10.1016/j.ijbiomac.2018.06.084openalex-snapshot
Advancement in the treatment of haemophilia
inferred← citeshttps://doi.org/10.1016/j.intimp.2024.112735openalex-snapshot
Anti-mCD20 in combination with α-mCXCL13 monoclonal antibody inhibits anti-FVIII antibody development in hemophilia A mice
inferred← citeshttps://doi.org/10.1016/j.jtha.2023.05.011openalex-snapshot
A review of the rationale for gene therapy for hemophilia A with inhibitors: one-shot tolerance and treatment?
inferred← citeshttps://doi.org/10.1016/j.jtha.2025.04.015openalex-snapshot
Outcomes of immune tolerance induction with rituximab to eradicate high-titer inhibitor of hemophilia A: depicted by exponential decay model and the gene expression profile of different outcomes by RNA-sequencing
inferred← citeshttps://doi.org/10.1016/j.jtha.2025.07.005openalex-snapshot
Impaired tolerance in the International Immune Tolerance Induction study due to the presence of very low-titer inhibitors
inferred← citeshttps://doi.org/10.1016/j.rpth.2024.102639openalex-snapshot
Intermediate-dose immune tolerance induction outperforms with faster success, less bleeding, and no added cost in comparison with low dose: a multicenter randomized clinical trial
inferred← citeshttps://doi.org/10.1016/j.thromres.2023.01.025openalex-snapshot
The efficacy of the rituximab-containing rescue-regimen for severe hemophilia A inhibitor children who relapsed following successful immune tolerance induction with rituximab in China
inferred← citeshttps://doi.org/10.1016/j.thromres.2023.02.011openalex-snapshot
The efficacy of sequential MMF-rescue-regimen to eradicate inhibitors for refractory severe hemophilia A inhibitor children in China
inferred← citeshttps://doi.org/10.1016/j.thromres.2023.02.016openalex-snapshot
Low-dose immune tolerance induction therapy in severe hemophilia a children in China: Starting earlier resulted in better inhibitor eradication outcomes
inferred← citeshttps://doi.org/10.1016/j.thromres.2024.109115openalex-snapshot
Large deletions and small insertions and deletions in the factor VIII gene predict unfavorable immune tolerance induction outcome in people with severe hemophilia A and high-responding inhibitors
inferred← citeshttps://doi.org/10.1016/j.tips.2023.10.002openalex-snapshot
Emerging approaches to induce immune tolerance to therapeutic proteins
inferred← citeshttps://doi.org/10.1016/j.transci.2019.08.008openalex-snapshot
Hemophilia A with inhibitor: Immune tolerance induction (ITI) in the mirror of time
inferred← citeshttps://doi.org/10.1016/j.yapd.2022.03.009openalex-snapshot
Advances in Hemophilia A Management
inferred← citeshttps://doi.org/10.1016/s0140-6736(24)02139-1openalex-snapshot
Haemophilia
inferred← citeshttps://doi.org/10.1055/s-0042-1748756openalex-snapshot
Immune Tolerance Induction (ITI) with a pdFVIII/VWF Concentrate (octanate) in 100 Patients in the Observational ITI (ObsITI) Study
inferred← citeshttps://doi.org/10.1080/14712598.2021.1940133openalex-snapshot
Bispecific antibodies for the treatment of hemophilia A
inferred← citeshttps://doi.org/10.1080/17474086.2021.1875817openalex-snapshot
Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors
inferred← citeshttps://doi.org/10.1097/mbc.0000000000001205openalex-snapshot
Hematological treatment and prophylaxis in patients with and without inhibitors
inferred← citeshttps://doi.org/10.1111/apt.14959openalex-snapshot
Letter: overcoming secondary loss of response to infliximab—it is not the drug, it is how you use it!
inferred← citeshttps://doi.org/10.1111/apt.14974openalex-snapshot
Letter: overcoming secondary loss of response to infliximab—it is not the drug, it is how you use it! Authors’ reply
inferred← citeshttps://doi.org/10.1111/ejh.70269openalex-snapshot
Determinants of Immune Tolerance Induction Outcomes in 237 Persons With Severe Hemophilia A
inferred← citeshttps://doi.org/10.1111/hae.13762openalex-snapshot
The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab
inferred← citeshttps://doi.org/10.1111/hae.14010openalex-snapshot
Optimizing the management of patients with haemophilia A and inhibitors in the era of emicizumab: Recommendations from a German expert panel
inferred← citeshttps://doi.org/10.1111/hae.14431openalex-snapshot
Predictors of inhibitor eradication by primary immune tolerance induction in severe haemophilia A with high responding inhibitors
inferred← citeshttps://doi.org/10.1111/hae.14577openalex-snapshot
Eradication of FIX inhibitor in haemophilia B children using low‐dose immune tolerance induction with rituximab‐based immunosuppressive agent(s) in China
inferred← citeshttps://doi.org/10.1111/jgh.16133openalex-snapshot
Dose intensification strategy influences infliximab pharmacokinetics but not clinical response after the same number of doses
inferred← citeshttps://doi.org/10.1111/jth.14779openalex-snapshot
Identification and functional characterization of a novel splicing variant in the F8 coagulation gene causing severe hemophilia A
inferred← citeshttps://doi.org/10.1111/jth.14887openalex-snapshot
Non‐additive effect on thrombin generation when a plasma‐derived factor VIII/von Willebrand factor (FVIII/VWF) is combined with emicizumab in vitro
inferred← citeshttps://doi.org/10.1111/jth.15878openalex-snapshot
Time between inhibitor detection and start of immune tolerance induction: Association with outcome in the BrazIT study
inferred← citeshttps://doi.org/10.1136/bmjopen-2021-057018openalex-snapshot
AKATSUKI study: a prospective, multicentre, phase IV study evaluating the safety of emicizumab under and immediately after immune tolerance induction therapy in persons with congenital haemophilia A with factor VIII inhibitors
inferred← citeshttps://doi.org/10.1172/jci159925openalex-snapshot
Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs
inferred← citeshttps://doi.org/10.1177/20406207241245511openalex-snapshot
Simoctocog alfa (Nuwiq ® ) in children: early steps in life’s journey for people with severe hemophilia A
inferred← citeshttps://doi.org/10.1182/bloodadvances.2022007267openalex-snapshot
Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication
inferred← citeshttps://doi.org/10.1186/s12887-022-03546-1openalex-snapshot
Emicizumab in children: bleeding episodes and outcome before and after transition to Emicizumab
inferred← citeshttps://doi.org/10.1186/s13099-025-00702-7openalex-snapshot
The role of probiotics in promoting systemic immune tolerance in systemic lupus erythematosus
inferred← citeshttps://doi.org/10.15446/rcciquifa.v54n3.120474openalex-snapshot
Historia de la hemofilia: una enfermedad que afecta a más de uno
inferred← citeshttps://doi.org/10.21115/jbes.v14.n1.p96-103openalex-snapshot
Statements about hemophilia A in Brazil: an expert Delphi panel
inferred← citeshttps://doi.org/10.21203/rs.3.rs-1520829/v1openalex-snapshot
Emicizumab in children: bleeding episodes and outcome before and after transition to Emicizumab
inferred← citeshttps://doi.org/10.21203/rs.3.rs-1520829/v2openalex-snapshot
Emicizumab in children: bleeding episodes and outcome before and after transition to Emicizumab
inferred← citeshttps://doi.org/10.2147/jbm.s443380openalex-snapshot
Risk of Intracranial Hemorrhage in Persons with Hemophilia A in the United States: Real-World Retrospective Cohort Study Using the ATHNdataset
inferred← citeshttps://doi.org/10.2147/tcrm.s205310openalex-snapshot
Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence
inferred← citeshttps://doi.org/10.21508/1027-4065-2023-68-3-107-116openalex-snapshot
Hemophilia in children - modern paradigms for treatment and prevention
inferred← citeshttps://doi.org/10.21682/2311-1267-2020-7-2-54-63openalex-snapshot
Results of a prospective observation on the use of a coagulation factor concentrate VIII concentrate (Octanate®) for the induction of immunological tolerance in patients with an inhibitory form of hemophilia A
inferred← citeshttps://doi.org/10.21682/2311-1267-2022-9-3-56-64openalex-snapshot
Is there any place for replacement therapy of hemophilia A in children in present and future?
inferred← citeshttps://doi.org/10.2174/1566523219666190924121836openalex-snapshot
Hemophilia Gene Therapy: New Development from Bench to Bed Side
inferred← citeshttps://doi.org/10.2196/45747openalex-snapshot
Quantifying Benefit-Risk Trade-Offs Toward Prophylactic Treatment Among Adult Patients With Hemophilia A in China: Discrete Choice Experiment Study
inferred← citeshttps://doi.org/10.24875/gmm.m20000451openalex-snapshot
Consenso de hemofilia en México
inferred← citeshttps://doi.org/10.24875/gmm.m21000463openalex-snapshot
Consensus on hemophilia in Mexico
inferred← citeshttps://doi.org/10.32471/umj.1680-3051.141.197975openalex-snapshot
Індукція імунної толерантності: стандарт лікування інгібіторної форми гемофілії
inferred← citeshttps://doi.org/10.32471/umj.1680-3051.141.198615openalex-snapshot
Шунтуючі препарати в лікуванні інгібіторної форми гемофілії
inferred← citeshttps://doi.org/10.33448/rsd-v11i13.35638openalex-snapshot
Impacto do desenvolvimento de inibidores no tratamento e qualidade de vida de pacientes com hemofilia: uma revisão de literatura
inferred← citeshttps://doi.org/10.3389/fimmu.2019.03078openalex-snapshot
Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies
inferred← citeshttps://doi.org/10.3389/fimmu.2020.01219openalex-snapshot
Hemophilia A Inhibitor Subjects Show Unique PBMC Gene Expression Profiles That Include Up-Regulated Innate Immune Modulators
inferred← citeshttps://doi.org/10.3389/fimmu.2022.1019275openalex-snapshot
Hemophilia a patients with inhibitors: Mechanistic insights and novel therapeutic implications
inferred← citeshttps://doi.org/10.34883/pi.2026.12.1.011openalex-snapshot
Результаты индукции иммунологической толерантности у детей с ингибиторной формой гемофилии А в Республике Беларусь
inferred← citeshttps://doi.org/10.3760/cma.j.issn.0253-2727.2018.10.001openalex-snapshot
[Chinese guidelines on the diagnosis and treatment of coagulation factor Ⅷ/Ⅸ inhibitors (version 2018)].
inferred← citeshttps://doi.org/10.3760/cma.j.issn.0253-2727.2019.10.001openalex-snapshot
[How I treat hemophilia with inhibitors].
inferred← citeshttps://doi.org/10.3760/cma.j.issn.0253-2727.2020.04.001openalex-snapshot
[Chinese guidelines on the treatment of hemophilia (version 2020)].
inferred← citeshttps://doi.org/10.4081/btvb.2026.467openalex-snapshot
Efficacy, safety and surgical management with concizumab prophylaxis in three young patients affected by severe hemophilia with inhibitors
inferred← citeshttps://doi.org/10.70675/6245f172z5eeez4b73zb616z0afe99c0a956openalex-snapshot
Traitement de l’hémophilie A à l’aide d’ARNm codant le facteur VIII et prévention de la réponse immunitaire dirigée contre le facteur VIII thérapeutique
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.